Introduction {#s1}
============

While three million women living with HIV (WLWH) give birth each year ([@R63]), the clinical guidance on reproductive health in this group has concentrated primarily on the health of the unborn baby and the prevention of mother-to-child transmission (MTCT) rather than on the expectant mother\'s health. Effective antiretroviral therapy (ART) has reduced MTCT and is less of a concern. With the majority of WLWH being of childbearing-age, reproductive health and rights and access to reproductive care have become important global issues but data are lacking. The purpose of this article is to review existing research and guidance on preconception considerations, contraception, maternal health and post-partum issues for WLWH, and to identify gaps in this evidence that require further investigation.

Methods {#s2}
=======

This article was written using scoping review methodology ([@R3]) to provide a narrative account of available research into preconception, contraception, maternal health and post-partum issues in WLWH. MEDLINE was searched for articles from 1950 to 2012 using diverse MeSH headings relevant to reproductive health in WLWH (Appendix). Relevant bibliographies, existing networks and HIV organisations, guidelines and conference abstracts were also reviewed, and experts in the field consulted regarding missing publications. Abstracts were scanned to determine if they were relevant to reproductive health in WLWH and to eliminate those focusing on the health of the unborn baby or the prevention of MTCT, before the full articles were reviewed. The quality of guidelines was assessed using the appraisal of guidelines for research and evaluation instrument ([@R7]).

Preconception considerations {#s3}
============================

Studies, including the meta-analysis by [@R46], have reported that between 26% and 57% of WLWH intend to have children ([@R37]; [@R49]). WLWH share the same rights as other women in terms of pregnancy and motherhood, but to fulfil these, access to general reproductive, preconception, pregnancy and post-partum counselling should be made to be a part of routine HIV care. This should include discussions about optimising HIV management, standard prenatal counselling, including healthy lifestyle advice, suitable conception options ([Table 1](#T1){ref-type="table"}), ART for the prospective mother and, potentially, child, as well as adoption and fertility options. An individual or couple should be referred for fertility assessment if there is no conception after 3--12 months (or earlier if the woman is \>35 years). Access to these services and costs vary geographically. In addition, access to adoption services can be limited, depending on country ([Table 2](#T2){ref-type="table"}).

###### 

Conception options for HIV concordant and discordant couples.

  -------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  HIV- woman and HIV + man   • IUI following sperm washing^[a](#T1-FN1){ref-type="table-fn"},[b](#T1-FN2){ref-type="table-fn"},[c](#T1-FN3){ref-type="table-fn"}^\
                             • Timed natural conception (only at ovulation; if effective viral suppression)^[a](#T1-FN1){ref-type="table-fn"},[b](#T1-FN2){ref-type="table-fn"},[c](#T1-FN3){ref-type="table-fn"}^\
                             • Natural conception (if effective viral suppression)^[a](#T1-FN1){ref-type="table-fn"},[b](#T1-FN2){ref-type="table-fn"},[c](#T1-FN3){ref-type="table-fn"}^\
                             • IVF or ICSI following sperm washing^[a](#T1-FN1){ref-type="table-fn"},[b](#T1-FN2){ref-type="table-fn"},[c](#T1-FN3){ref-type="table-fn"}^\
                             • Insemination of donor sperm at ovulation^[a](#T1-FN1){ref-type="table-fn"},[b](#T1-FN2){ref-type="table-fn"},[c](#T1-FN3){ref-type="table-fn"}^\
                             • PrEP with timed natural conception (only at ovulation; if effective viral suppression)^[a](#T1-FN1){ref-type="table-fn"},[b](#T1-FN2){ref-type="table-fn"},[c](#T1-FN3){ref-type="table-fn"},[d](#T1-FN4){ref-type="table-fn"}^\
                             • Adoption^[a](#T1-FN1){ref-type="table-fn"},[b](#T1-FN2){ref-type="table-fn"}^

                             

  HIV+ woman and HIV− man    • Home artificial insemination with partner\'s sperm during ovulation^[a](#T1-FN1){ref-type="table-fn"},[c](#T1-FN3){ref-type="table-fn"}^\
                             • Timed natural conception (only at ovulation; if effective viral suppression)^[a](#T1-FN1){ref-type="table-fn"},[b](#T1-FN2){ref-type="table-fn"},[c](#T1-FN3){ref-type="table-fn"}^\
                             • Natural conception (if effective viral suppression)^[a](#T1-FN1){ref-type="table-fn"},[b](#T1-FN2){ref-type="table-fn"},[c](#T1-FN3){ref-type="table-fn"}^\
                             • Assisted reproduction in case of fertility disorders including IUI, IVF, ICSI^[a](#T1-FN1){ref-type="table-fn"},[b](#T1-FN2){ref-type="table-fn"},[c](#T1-FN3){ref-type="table-fn"}^\
                             • PrEP with timed natural conception (only at ovulation; if effective viral suppression)^[a](#T1-FN1){ref-type="table-fn"},[b](#T1-FN2){ref-type="table-fn"},[c](#T1-FN3){ref-type="table-fn"}^\
                             • Adoption^[a](#T1-FN1){ref-type="table-fn"},[b](#T1-FN2){ref-type="table-fn"}^

                             

  HIV+ woman and HIV+ man    • Timed natural conception (only at ovulation; if effective viral suppression)^[a](#T1-FN1){ref-type="table-fn"},[b](#T1-FN2){ref-type="table-fn"},[c](#T1-FN3){ref-type="table-fn"}^\
                             • Natural conception (if effective viral suppression)^[a](#T1-FN1){ref-type="table-fn"},[b](#T1-FN2){ref-type="table-fn"},[c](#T1-FN3){ref-type="table-fn"}^\
                             • IUI following sperm washing^[a](#T1-FN1){ref-type="table-fn"},[b](#T1-FN2){ref-type="table-fn"}^\
                             • Insemination of donor sperm at ovulation^[a](#T1-FN1){ref-type="table-fn"},[b](#T1-FN2){ref-type="table-fn"}^\
                             • Assisted reproduction in case of fertility disorders including IUI, IVF, ICSI^[a](#T1-FN1){ref-type="table-fn"},[b](#T1-FN2){ref-type="table-fn"},[c](#T1-FN3){ref-type="table-fn"}^\
                             • Adoption^[a](#T1-FN1){ref-type="table-fn"},[b](#T1-FN2){ref-type="table-fn"}^
  -------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

IUI, intrauterine insemination; IVF, in vitro fertilisation; ICSI, intracytoplasmic sperm injection; PrEP, pre-exposure prophylaxis.

[@R39].

[@R19].

[@R15].

[@R65].

###### 

Fertility and adoption guidelines in European countries, Canada and the USA.^[a](#T2-FN1){ref-type="table-fn"}^

  Country           Availability of privately funded assisted reproduction?   Availability of publically funded assisted reproduction?   Is adoption an option?   Availability of guidelines?   Guideline reference
  ----------------- --------------------------------------------------------- ---------------------------------------------------------- ------------------------ ----------------------------- ---------------------
  Canada            Yes                                                       Yes^[b](#T2-FN2){ref-type="table-fn"}^                     Yes                      Yes                           [@R39]
  Denmark           N/A                                                       Yes                                                        No                       Yes                           [@R10]
  France            N/A                                                       Yes                                                        Yes                      Yes                           [@R51]
  Germany/Austria   Yes[^c^](#T2-FN3){ref-type="table-fn"}                    Yes[^c^](#T2-FN3){ref-type="table-fn"}                     Yes, challenging         Yes                           [@R15]
  Italy             Yes[^d^](#T2-FN4){ref-type="table-fn"}                    Yes[^d^](#T2-FN4){ref-type="table-fn"}                     Yes, challenging         Yes                           [@R43]
  Portugal          Yes                                                       Yes[^d^](#T2-FN4){ref-type="table-fn"}                     Yes, challenging         No                            
  Romania           Yes[^d^](#T2-FN4){ref-type="table-fn"}                    No                                                         Yes, challenging         Yes                           [@R40]
  Spain             Yes                                                       Yes[^d^](#T2-FN4){ref-type="table-fn"}                     Yes, challenging         Yes                           [@R26]
  UK                Yes                                                       Yes[^d^](#T2-FN4){ref-type="table-fn"}                     Yes, challenging         Yes                           [@R19]
  USA               Yes                                                       No                                                         Yes                      Yes                           [@R60]

N/A, not applicable.

Information included in this table has been collected from Women for Positive Action faculty members.

3 cycles of IVF are covered in Quebec; 40% fertility tax credit up to \$20,000 is available in Manitoba; IVF is covered for bilateral tube blockage in Ontario; several other provinces have petitions to cover IVF under review.

50% of three treatment cycles covered by statutory health insurance.

Available in a limited number of centres.

There is a lack of information about conception planning and pregnancy for those wishing to have children ([@R31]). [@R47] found evidence of inadequate knowledge among people living with HIV (PLWHIV) about pregnancy, despite having regular access to a healthcare professional, and reported that ethnicity influenced the degree of knowledge. PLWHIV and healthcare providers globally have indicated that access to clinical guidelines, pamphlets, workshops and peer-counselling and support are important tools to optimise the care of PLWHIV during preconception and conception ([@R19]; [@R31]). Preconception and conception guidelines currently available across Europe, Canada and USA are outlined in [Table 2](#T2){ref-type="table"}.

Family planning and contraception {#s4}
=================================

Among WLWH, the proportion of unintended pregnancies is high at 50--83% ([@R20]; [@R33]; [@R38]). Tailored reproductive counselling and contraception discussions early in the course of HIV care are crucial for all women to prevent unintended pregnancies. A variety of contraceptive options are available ([Table 3](#T3){ref-type="table"}) and the choice should take into account potential interactions with ART ([Table 4](#T4){ref-type="table"}). A recent study has reported that women using hormonal contraceptives, specifically depot medroxyprogesterone acetate (DMPA), had twice the risk of acquiring or transmitting HIV as other women ([@R28]). A sub-analysis of the Methods for Improving Reproductive Health in Africa study found that combined oral contraceptive (COC) or progesterone only pills (POP) use was not associated with an increased risk of HIV acquisition \[COC: HRa 0.94, 95% CI 0.63--1.39; POP: HRa 0.84, 95% CI 0.45--1.56\], but progesterone only injectable contraceptive methods (DMPA and norethisterone enantate) were \[HRa 1.41, 95% CI 1.04--1.91\], ([@R41]).

###### 

Advantages and disadvantages of contraception options in HIV ([@R62]).

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Method                                                    Advantages                                              Disadvantages^[a](#T3-FN1){ref-type="table-fn"}^
  --------------------------------------------------------- ------------------------------------------------------- -------------------------------------------------------
  Condoms (male)                                            • STI/HIV protection                                    • Partner cooperation needed\
                                                                                                                    • Requires correct technique\
                                                                                                                    • Inconvenient/may interfere with sexual intercourse\
                                                                                                                    • Pregnancy prevention = 85%

                                                                                                                    

  Condoms (female)                                          • STI/HIV protection\                                   • Requires correct technique\
                                                            • Can be controlled by the woman                        • Inconvenient/may interfere with sexual intercourse\
                                                                                                                    • Pregnancy prevention = 79%\
                                                                                                                    • Price and availability

                                                                                                                    

  Oral contraceptive pill                                   • Effective\                                            • Drug-drug interactions\
                                                            • Less blood loss\                                      • Possibly increased viral shedding\
                                                            • Can be controlled by the woman\                       • No STI/HIV protection
                                                            • Pregnancy prevention = 92%                            

                                                                                                                    

  Patch, ring, injectable combination                       • Effective\                                            • Drug-drug interactions?\
                                                            • Less blood loss\                                      • Lack of data\
                                                            • Can be controlled by the woman\                       • Increased viral shedding?\
                                                            • Pregnancy prevention = patch: 92%; ring: 92%          • No STI/HIV protection

                                                                                                                    

  DMPA                                                      • Low maintenance\                                      • No STI/HIV protection\
                                                            • Effective\                                            • Possibly increased risk of HIV acquisition
                                                            • Can be controlled by the woman\                       
                                                            • Pregnancy prevention = 97%                            

                                                                                                                    

  Copper intra-uterine device                               • Convenient\                                           • Blood loss\
                                                            • Effective\                                            • Increased pelvic infection\
                                                            • Can be controlled by the woman\                       • No STI/HIV protection
                                                            • Pregnancy prevention = 99.2%                          

                                                                                                                    

  Levonorgestrel-releasing intra-uterine system (LNG-IUS)   • Long lasting\                                         • Blood loss\
                                                            • Convenient\                                           • No STI/HIV protection\
                                                            • Can be controlled by the woman\                       • Minimal research available in HIV
                                                            • Pregnancy prevention = 99.8%                          

                                                                                                                    

  Cervical barrier                                          • Some STI protection\                                  • Increased urinary tract infections\
                                                            • Good contraceptive effectiveness if used correctly\   • Requires correct technique\
                                                            • Can be controlled by the woman\                       • No STI/HIV protection
                                                            • Pregnancy prevention = 84%                            

                                                                                                                    

  Sterilisation                                             • Low maintenance\                                      • Irreversible\
                                                            • Effective\                                            • Expensive\
                                                            • Can be controlled by the woman\                       • Invasive\
                                                            • Pregnancy prevention = 99.5%                          • No STI/HIV protection
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------

STI, sexually transmitted infection; HIV, human immunodeficiency virus.

Pregnancy prevention: The percentage of women who did not experience an unintended pregnancy during the first year of typical use of contraception in the USA.

###### 

Drug interactions between hormonal contraception and various antiretroviral agents.^[a](#T4-FN1){ref-type="table-fn"}^

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Antiretroviral agent                                       Effect on drug concentration               Recommended action
  ---------------------------------------------------------- ------------------------------------------ -----------------------------------------------------------------
  *Protease inhibitors (PI)*                                                                            

  Atazanavir (ATV)                                           ↑ EE AUC 48%\                              OK for use OCP should contain\
                                                             ↑ NE AUC 110%                              ≤ 30mcg EE. Monitor for side effects, or use alternative method

  Atazanavir/ritonavir (ATV/r)                               ↓ EE\                                      OK for use OCP should contain\
                                                             ↑ norgestimate (active metabolite of NG)   ≥35mcg EE

  Darunavir (DRV), Darunavir/ritonavir (DRV/r)               ↓ EE AUC 44%\                              Do not use
                                                             ↓ NE AUC 14%                               

  Fosamprenavir (FPV)                                        With amprenavir: ↑ EE, ↑ NE\               Do not use
                                                             ↓ amprenavir C^min^ 20%                    

  Fosamprenavir/ritonavir (FPV/r)                            ↓ EE AUC 37%\                              Do not use
                                                             ↓ NE AUC 34%                               

  Lopinavir/ritonavir (LPV/r)                                ↓ EE AUC 42%\                              Do not use
                                                             ↓ NE AUC 17%                               

  Nelinavir (NFV)                                            ↓ EE AUC 47%\                              Do not use
                                                             ↓ NE AUC 18%                               

  Saquinavir/ritonavir (SQV/r)                               ↓ EE\                                      Do not use
                                                             SQV kinetics not affected by OCP           

  Tipranavir/ritonavir (TPV/r)                               ↓ EE AUC 48%\                              Do not use
                                                             NE: no significant change                  

  *Nonnucleoside reverse transcriptase inhibitors (NNRTI)*                                              

  Efavirenz (EFV)                                            ↓ NG AUC 64%\                              Do not use
                                                             ↓ LN AUC 83%\                              
                                                             EE: no effect                              

  Etravirine (ETR)                                           ↑ EE AUC 22%\                              OK for use
                                                             NE: No significant change                  

  Nevirapine (NVP)                                           ↓ EE AUC 20%\                              Do not use
                                                             ↓ NE AUC 19%                               

  Rilpivirine (RPV)                                          ↑ EE AUC 14%\                              OK for use
                                                             NE: no significant change                  

  *Integrase inhibitor*                                                                                 

  Raltegravir (RAL)                                          No significant interaction                 OK for use

  Elvitegravir (ELV)^[b](#T4-FN2){ref-type="table-fn"}^      ↓ EE AUC 25%                               OK for use OCP should contain\
                                                                                                        ≤ 30mcg EE. Await more data

  *CCR5 antagonist*                                                                                     

  Maraviroc (MRV)                                            No significant interaction                 OK for use
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

AUC, area under the time concentration curve (drug exposure); C^min^, minimum concentration; EE, ethinyl estradiol; LN, levonorgestrel; NE, norethindrone; NG, norgestimate; OCP, oral contraceptive pill.

Adapted from [@R12], [@R13], [@R14].

When taken as a elvitegravir/cobicistat/FTC/tenofovir fixed dose 'quad' formulation ([@R22]).

The Centers for Disease Control and Prevention have recently published updated guidance stating that (1) the use of hormonal contraceptives, including COC, POP, DMPA and implants, are safe for women at high risk for HIV infection or infected with HIV and (2) all women who use contraceptive methods other than condoms should be counselled regarding the use of condoms and the risk for sexually transmitted infections (STIs; [@R59]). However, a clarification is added to the recommendation for women at high risk for HIV infection who use DMPA or norethisterone enantate to acknowledge the inconclusive evidence regarding the association between progestin-only injectable use and HIV acquisition.

Since condoms are poor at preventing pregnancy, but required to prevent HIV and STIs, dual protection including a hormonal contraceptive (or copper intrauterine device) and a condom is recommended ([@R12]; [@R70]).

Maternal health, HIV and pregnancy {#s5}
==================================

Complications during childbirth lead to the death of one woman every minute (approximately 529,000 each year) ([@R64]). Prior to combination ART, pre-eclampsia was an uncommon complication of pregnancy in WLWH ([@R58]). Although the benefits of taking ART during pregnancy outweigh the risks, the incidence of preeclampsia has now risen to a rate similar to that reported among the general population ([@R17]; [@R68]) and the mother should be closely monitored ([@R36]). Limited data show a higher prevalence of gestational diabetes in WLWH (2--5% in industrialised countries) compared with the general population ([@R23]). However, the risk factors in WLWH are largely unclear and the data are contradictory ([@R66]).

Current guidance on whether ART should be continued or stopped in WLWH with CD4 counts \>500 cells/mm^3^ following delivery remain unclear and data from ongoing trials are awaited. However, treatment interruptions guided by CD4 cell counts appear to put PLWHIV at an increased risk of disease progression ([@R57]), and there is a trend towards an increased risk of AIDS or all-cause mortality in women who stopped taking ART within 90 days of delivery ([@R42]). Recent UK guidelines recommend that when stopping non-nucleoside reverse transcriptase inhibitor (NNRTI)-based ART post-partum the NNRTI washout period should be covered by two weeks of protease inhibitor (PI)-based therapy ([@R11]). Cessation of maternal ART in the first year afterbirth has little effect on CD4 levels, but it does have an effect on immune activation ([@R67]). Considerations of adherence, the overall health of the mother, and her readiness to continue treatment during the post-partum phase need to be assessed on an individual basis, in collaboration with the mother.

Perinatal and post-partum considerations {#s6}
========================================

Perinatal depression refers to depression occurring during pregnancy or up to one-year after the birth and includes post-partum depression. Perinatal depression is a common phenomenon ([@R32]). In a review from [@R21], the prevalence of major depression during pregnancy and post-partum ranged from 3.1% to 4.9% and 1.0% to 5.9%, respectively. As PLWHIV are more likely to suffer from depression, WLWH may be at an even higher risk of perinatal depression ([@R29]; [@R56]).

Factors that may contribute to increased perinatal depression in WLWH include maternal guilt, fear of transmitting HIV to the newborn, concerns related to disclosure, stigma and the negative impacts of maternal HIV on their children, preconception substance use, multiple preconception sexual partners, lower socio-economic status, medication adherence problems, multiparity, lower CD4 pregnancy nadir and impaired physical and cognitive functioning ([@R8]; [@R25]; [@R32]; [@R35]; [@R45]; [@R50]; [@R53]; [@R55]). Some causal factors are potentially modifiable, including lack of emotional and social support, especially from the partner, intimate partner violence, ineffective coping and a history of psychiatric/depressive symptoms ([@R2]; [@R4]; [@R5]; [@R9]; [@R24]; [@R27]; [@R29]; [@R30]; [@R52]; [@R55]). Evidence indicating an association between perinatal depression and adverse obstetric and infant developmental outcomes is conflicting. Studies have linked perinatal depression with obstetric complications, neonatal faltering growth, and learning disorders ([@R1]; [@R48]). Others have reported a lack of association ([@R18]; [@R27]; [@R32]).

Breastfeeding {#s7}
=============

Several conflicting guidelines on HIV and breastfeeding have been published ([Table 5](#T5){ref-type="table"}). ART can reduce the risk of MTCT via breast milk by over 50% ([@R34]). While breastfeeding with ART prophylaxis is not as effective as formula feeding in preventing MTCT, lower infant mortality rate with breastfeeding and comparable HIV-free survival for both feeding methods at 18 months have been reported. Therefore, exclusive breastfeeding is recommended in resource-poor countries ([@R61]; [@R69]).

###### 

Available global and European countries' breastfeeding guidelines

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Guidelines                          Country   Guidance on breastfeeding for mothers living with HIV
  ----------------------------------- --------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  WHO (in collaboration with [@R63]   Global    • Mothers with HIV should be counselled about the risks and benefits of infant feeding and provided with specific guidance regarding their situation\
                                                • Mothers who choose to breastfeed should be supported in their choice\
                                                • Mothers who choose not to breastfeed should be provided with guidance and support around formula feeding\
                                                • In low and middle income countries exclusive breastfeeding is recommended for the first six months of life

  [@R6]                               UK        • In the UK, mothers with HIV are recommended to refrain from breastfeeding from birth regardless of maternal viral load and ART\
                                                • All mothers with HIV should be supported to formula feed their infant\
                                                • In rare circumstances where a mother who is effective on combination ART with a repeatedly undetectable viral load chooses to breastfeed then maternal ART should be carefully monitored and continued until one week after all breastfeeding has ceased. Breastfeeding should be ceased by 6 months

  [@R54]                              UK        • All mothers with HIV should avoid breastfeeding\
                                                • Women should be given supportive advice about formula feeding

  [@R16]                              Germany   • Mothers are advised not to breastfeed, according to WHO guidelines

  [@R26]                              Spain     • All mothers with HIV should avoid breastfeeding\
                                                • Women should be given supportive advice about formula feeding\
                                                • Formula is provided free of charge through the Public Health System

  [@R43]                              Italy     • All mothers with HIV should avoid breastfeeding\
                                                • Formula is provided free of charge through the National Health System

  [@R51]                              France    • All mothers with HIV should avoid breastfeeding\
                                                • Mothers with HIV should be counselled about the risks of breastfeeding and be given supportive advice about formula feeding
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In some communities, a mother risks revealing her HIV status by not breastfeeding ([@R44]), and becoming a target for discrimination. For this reason, some guidelines now recommend supporting women in breastfeeding while taking ART if necessary ([@R6]; [@R64]).

Summary of knowledge gaps and research needs in the topic of reproductive health for WLWH {#s8}
=========================================================================================

1.  Preconception medical management in WLWH and couples wishing to parent;

2.  Optimal contraception methods for WLWH;

3.  Influence of hormonal contraception on HIV transmission;

4.  Safety and pharmacokinetics of newer ART regimens during pregnancy;

5.  Association between HIV-related factors and maternal health outcomes;

6.  Safety of stopping ART in WLWH who wish to cease treatment;

7.  Issues in motherhood including stigma, discrimination, perinatal depression and emotional well-being and

8.  Optimal method of infant feeding.

Conclusions {#s9}
===========

Working towards answering the many questions around reproductive and maternal health and emotional well-being both during and post-pregnancy in WLWH will help us optimise the health care for WLWH around the world. Addressing these gaps in the literature will direct the development of revised practice guidelines reflecting the specific needs of WLWH.

Women for Positive Action is a global initiative established in response to the need to address specific concerns of women living and working with HIV. Women for Positive Action is made up of healthcare professionals, WLWH and community group representatives from Canada, Europe and Latin America. Working together, the Women for Positive Action group aims to empower, educate, and support WLWH and the healthcare professionals and community advocates/leaders involved in their treatment; to explore the issues facing WLWH and provide meaningful, educational-based support to respond to these needs; and to contribute towards an enhanced quality of life for WLWH. For further information on this initiative please visit [www.womenforpositiveaction.org](http://www.womenforpositiveaction.org). Women for Positive Action (WFPA) faculty who contributed to this article: Larissa Afonina (Russia), Adriana Ammassari (Italy), Jane Anderson (UK), Teresa Branco (Portugal), Elisabeth Crafer (UK), Antonella d\'Arminio Monforte (Italy), Annette Haberl (Germany), Margaret Johnson (UK), Karine Lacombe (France), Anne-Mette Lebech (Denmark), Mona Loutfy (Canada), Mariana Mãrdärescu (Romania), Fiona Mulcahy (Ireland), Angelina Namiba (UK), Ophelia Haanyama Ørum (Sweden), Maria Jesús Pérez Elias (Spain), Annette Piecha (Germany), Lorraine Sherr (UK), Ulrike Sonnenberg-Schwan (Germany), Winnie Ssanyu-Sseruma (UK) and Sharon Walmsley (Canada). We also acknowledge Litmus MME who provided medical writing support to the Women for Positive Action faculty. Women for Positive Action is an educational program funded and initiated by Abbott Laboratories.

The database of MEDLINE was searched from 1950 to 2012 using appropriate MeSH headings for each section including "HIV" and "women" and "reproduction" or "pregnancy planning" or "preconception," "contraception" or "family planning," "maternal health," "post-partum depression," "perinatal depression," "breastfeeding," "reproductive health" and "stigma" or "discrimination".
